NDATOPICALJELLY
Approved
Mar 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
XYLOCAINE (lidocaine hydrochloride) by AstraZeneca is 12. First approved in 1953.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XYLOCAINE (lidocaine hydrochloride) is a local anesthetic jelly formulation that stabilizes neuronal membranes by inhibiting ionic fluxes required for impulse initiation and conduction. It is indicated for topical anesthesia and has been a standard-of-care product since 1953. The drug works through membrane stabilization to produce rapid, localized numbing effects.
$0.005BPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D utilization (527 claims in 2023), signaling a mature, stable commercial footprint with limited growth opportunity.
Mechanism of Action
12.1 Mechanism of Action Lidocaine hydrochloride stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. 12.2 Pharmacodynamics Excessive blood levels may cause changes in cardiac output, total…
Worked on XYLOCAINE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.